Synta Pharmaceuticals stock soars on breast cancer results; stock up 1.92 (37.94%) @ 2:00 PM EDT

Source :: Chemical Business Newsbase. July 29, 2013
Publication Year :: 2013
Abstract: Synta Pharmaceuticals Corp announced that preliminary results from the ENCHANT-1 clinical trial, which evaluates ganetespib monotherapy in patients with newly diagnosed locally advanced or metastatic HER2 positive or triple-negative breast [...]

Subjects :: Synta Pharmaceuticals Corp. -- Company sales and earnings
Stocks -- Prices and rates
Breast cancer -- Drug therapy
Pharmaceutical industry -- Company sales and earnings
Company earnings/profit
Business
Chemicals, plastics and rubber industries

Tools